Sopherion Therapeutics

closed

Sopherion has the US and Canadian rights to this liposomal nanotechnology that targets the tumor vasculature.

Launch date

2001

Employees

Market cap

Enterprise valuation

New Brunswick New Jersey (HQ)

Date	Investors	Amount	Round
Mar 2003	HealthCap Johnson & Johnson Development Corporation ProQuest Investments Intersouth Partners Connecticut Innovations TL Ventures GE Capital Life Science and Technology Finance Seaflower Ventures	$26.0m	Series A
Sep 2004	HealthCap Canaan Sprout Group ProQuest TL Ventures Seaflower Ventures NewSpring Ventures	$47.0m	Series B
Jan 2008	Canaan New Leaf Venture Partners ProQuest Investments NewSpring Capital TL Ventures Devon Park BioVentures Zoticon BioVentures	$35.0m	Late VC
Feb 2009	Zoticon BioVentures	$55.0m	Series C
Total Funding		€148m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about Sopherion Therapeutics